Linxens Sweden AB – FDA 483, Nov 7, 2024

During a U.S. Food and Drug Administration (FDA) inspection conducted from November 4 to November 7, 2024, medical device manufacturer Linxens Sweden AB, located in Angelholm Skane, Sweden, was issued an FDA Form 483. This document highlighted observed conditions and practices requiring attention. The primary finding detailed in the report indicated deficiencies in the company's process validation activities. Specifically, the Operational Qualification (OQ) for manufacturing processes lacked adequate documentation to clearly define process control limits and action levels, which are critical for maintaining product quality and safety. These observations were issued pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, which guides the FDA in reporting conditions that may indicate a deviation from regulatory compliance. The purpose of such reports is to assist companies like Linxens Sweden AB in ensuring adherence to the Act and its regulations. The firm acknowledged the observations and indicated a commitment to correct the identified issues. Linxens Sweden AB is required to formally respond to the FDA, detailing the corrective actions taken or planned to address these findings.